PERKINELMER BOOSTS LIMS PRODUCTIVITY

Styled after the familiar Microsoft Outlook graphical interface, the new LABWORKS software uses a tree structure, menu bar, tool bar and icons known for their exceptional ease of use. New and experienced users will save time through fewer clicks to accomplish the same tasks as before. Through the improved, highly intuitive interface, new users will have a sharply reduced learning curve.

“LABWORKS has always been a powerful tool for lab automation,” said Stephen Delity, business unit leader, BioAnalytical Solutions, at PerkinElmer Life and Analytical Sciences. “With this new release, tapping the power of LABWORKS becomes significantly easier. In addition, we have also focused on providing the consistency demanded by rigorously regulated environments. On both scores, this is an important update to LABWORKS.”

This is the second quarterly update this year to the LABWORKS software and is part of PerkinElmer’s new update policy, which brings new functionality to users every three months. Users have the option to update LABWORKS each quarter or can update less frequently. PerkinElmer studies have shown, however, that regular updates contribute to productivity gains and reduce disruptions to workflow as changes are introduced more incrementally during a frequent update cycle.

The first quarter LABWORKS update focused on significantly improving scheduling, organizing and reporting of critical laboratory data. Among the new capabilities was a Process Scheduler module used to schedule routine sampling and to monitor sample statuses throughout an organization based on time, frequency, sample locations, and type of analysis. Other additions included a sophisticated new query function that makes it easy for users to work with data in both LABWORKS and outside databases.

For more information about LABWORKS ES LIMS software from PerkinElmer, contact PerkinElmer at 1-800-762-4060 or visit www.perkinelmer.com .

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions are intended to identify forward-looking statements. There are a number of important risk factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our failure to introduce new products in a timely manner, the impact of our debt on our cash flow and investment opportunities, our ability to comply with financial covenants contained in our credit agreements and debt instruments, our international operations, cyclical downturns continuing to affect several of the industries into which we sell our products, our ability to adjust our operations to address unexpected changes, the successful integration of our Life Sciences and Analytical Instruments business units, our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business, the loss of any of our licenses that may require us to stop selling products or lose competitive advantage, competition, regulatory compliance, regulatory changes, our failure to obtain and enforce intellectual property protection, our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets, as well as other factors which we describe under the caption “Forward-Looking Information and Factors Affecting Future Performance” in our most recently filed annual report on Form 10-K and in our most recently filed quarterly report on Form 10-Q. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer, Inc. is a global technology leader focused in the following businesses – Life and Analytical Sciences, Optoelectronics and Fluid Sciences. Combining operational excellence and technology expertise with an intimate understanding of our customers’ needs, PerkinElmer provides products and services in health sciences and other advanced technology markets that require innovation, precision and reliability. The Company serves customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com  or 1-877-PKI-NYSE.